STAGE
1-A and 1-B
Figure 2. Management Recommendations
MANAGEMENT FOLLOW-UP
2
3 or 4
Observation
(III, G, S)
• Follow up at 2–4 month intervals
in the absence of new symptoms.
(III, G, D)
• Recommend prompt return if
new symptoms develop.
(III, G, S)
• Encourage monocular visual
acuity testing with Amsler grid.
(III, G, S)
Vitreoretinal surgery
a
(I++, G, S)
Vitreopharmacolysis
b
(III, In, D)
• Follow up at 1–2 days
postoperatively, then 1–2 weeks.
(III, G, S)
• Frequency and timing of
subsequent visits varies
depending on the outcome of
surgery and the patient's clinical
course. (III, G, D)
• If no surgery, follow-up every
2–4 months. (III, G, D)
• Follow up at 1 week and 4 weeks,
or with new symptoms (e.g.,
retinal detachment symptoms).
(III, G, D)
Vitreoretinal surgery
(I++, G, S)
• Follow up at 1–2 days
postoperatively, then 1–2 weeks.
(III, G, D)
• Frequency and timing of
subsequent visits varies
depending on the outcome of
surgery and the patient's clinical
course. (III, G, D)
a
Although surgery is usually performed, observation may also be appropriate in selected cases.
b
Although ocriplasmin has been approved by the U.S. Food and Drug Administration for VMA, its use
for treatment of idiopathic macular hole without VMA would currently be considered off-label use.
